Skip Navigation


Brain Advance Access originally published online on June 9, 2005
Brain 2005 128(9):2164-2174; doi:10.1093/brain/awh558
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
128/9/2164    most recent
awh558v2
awh558v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Krishnan, A. V.
Right arrow Articles by Kiernan, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krishnan, A. V.
Right arrow Articles by Kiernan, M. C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2005). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Altered motor nerve excitability in end-stage kidney disease

Arun V. Krishnan1,2, Richard K. S. Phoon3, Bruce A. Pussell3, John A. Charlesworth3, Hugh Bostock4 and Matthew C. Kiernan1,2

1 Institute of Neurological Sciences, Prince of Wales Hospital, Randwick, Sydney, Australia, 2 Prince of Wales Medical Research Institute and Prince of Wales Clinical School, University of New South Wales, 3 Department of Nephrology, Prince of Wales Hospital, Randwick, Sydney, Australia and 4 Sobell Department of Neurophysiology, Institute of Neurology, Queen Square, London, UK

Correspondence to: Dr Matthew Kiernan, Prince of Wales Medical Research Institute, Barker Street, Randwick, Sydney, NSW 2031, Australia E-mail: M.kiernan{at}unsw.edu.au

Although multiple toxins have been implicated in the development of uraemic neuropathy, no causative agent has been identified. In the present study, the excitability properties of lower limb motor nerves in patients with end-stage kidney disease treated with haemodialysis were measured before, during and after a standard 5 h haemodialysis session, in an attempt to explore the pathophysiology of uraemic neuropathy. Compound muscle action potentials were recorded from tibialis anterior and extensor digitorum brevis, following stimulation of the common peroneal nerve in 14 patients. Measures of excitability were assessed in relation to changes in serum levels of potential neurotoxins, including potassium, calcium, urea, uric acid, parathyroid hormone and ß-2-microglobulin. Before dialysis, measures of nerve excitability were significantly abnormal in the patient group for axons innervating tibialis anterior and extensor digitorum brevis, consistent with axonal depolarization: refractoriness was increased and superexcitability and depolarizing threshold electrotonus were reduced. Pre-dialysis excitability abnormalities were strongly correlated with serum K+. Correlation was also noted between the severity of symptoms and excitability abnormalities. Haemodialysis normalized the majority of nerve excitability parameters. In conclusion, lower limb motor axons in uraemic patients are depolarized before dialysis. The correlation between serum K+ and excitability measures indicates that hyperkalaemia is primarily responsible for uraemic depolarization, and a likely contributing factor to the development of neuropathy.

Key Words: membrane potential; nerve excitability; potassium; threshold electrotonus; uraemic neuropathy

Abbreviations: ß-2M = ß-2-microglobulin; CMAP = compound muscle action potential; EDB = extensor digitorum brevis; ESKD = end-stage kidney disease; NCS = nerve conduction study; NSS = neuropathy symptom score; PTH = parathyroid hormone; SNAP = sensory nerve action potential; TA = tibialis anterior; TEd = depolarizing threshold electrotonus; TEh = hyperpolarizing threshold electrotonus; T-NSS = total neuropathy symptom score

Received February 24, 2005. Revised April 10, 2005. Accepted May 12, 2005.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
NEJMHome page
T. W. Meyer and T. H. Hostetter
Uremia
N. Engl. J. Med., September 27, 2007; 357(13): 1316 - 1325.
[Full Text] [PDF]


Home page
BrainHome page
W. J. Z'Graggen, C. S. Y. Lin, R. S. Howard, R. J. Beale, and H. Bostock
Nerve excitability changes in critical illness polyneuropathy
Brain, September 1, 2006; 129(9): 2461 - 2470.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
A. V. Krishnan, R. K. S. Phoon, B. A. Pussell, J. A. Charlesworth, H. Bostock, and M. C. Kiernan
Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease
Brain, June 1, 2006; 129(6): 1585 - 1592.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
A V Krishnan, R K S Phoon, B A Pussell, J A Charlesworth, and M C Kiernan
Sensory nerve excitability and neuropathy in end stage kidney disease
J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 548 - 551.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.